CEO exercised or converted 118K ROIV derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Dec 24, 2025
- Reporting period
- Not applicable
- Filed with the SEC
- Dec 30, 2025
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001140361-25-046786
Filed / recordedDec 30, 2025, 7:00 AM UTCAdded to OQROOct 6, 2026, 8:46 PM UTC Data qualityVerified: identifiers matched exactly IssuerRoivant Sciences Ltd. Reporting personEric Venker Officer titlePresident & Immunovant CEO TableNon-derivative (Table I) Transaction dateDec 24, 2025 Acquired / disposedAcquired (A) Shares owned after1,729,597 Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.